Anhidrotic effect of intradermal injections of botulinum toxin: A comparison of different products and concentrations

Acta Dermato-Venereologica

Volumn 88, Issue 3, 2008, Pages 229-233

  Rystedt, Alma ^a   Swartling, Carl ^a   Naver, Hans ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Botox; Botulinum toxin; Dilution; Dysport; Hyperhidrosis; Neurobloc

Indexed keywords

ANTIPERSPIRANT AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; IODINE; STARCH;

ANHIDROSIS; ARTICLE; CONTROLLED STUDY; DILUTION; DRUG EFFECT; DRUG FORMULATION; HUMAN; HUMAN EXPERIMENT; HYPOTHESIS; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; AGED; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERHIDROSIS; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; PILOT PROJECTS; SWEATING;

EID: 44349103779     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0419     Document Type: Article

References (18)

1. Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003; 29: 7-13.
2. Summary of product characteristics [cited 2007 May 28]. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/neurobloc/neurobloc.htm
3. Carruthers A, Carruthers J. Toxins 99, new information about the botulinum neurotoxins. Dermatol Surg 2000; 26: 174-176.
4. Pickett A, O'Keeffe R, Panjwani N. The protein load of therapeutic botulinum toxins. Eur J Neurol 2007; 14: e11.
5. Wohlfarth K, Göschel H, Frevert J, Dengler R, Bigalke H. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 335-340.
6. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72: 459-462.
7. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998; 64: 6-12.
8. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - assuming a ratio of 4:1. Mov Disord 1997; 12: 1013-1018.
9. Durif F. Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur J Neurol 1995; 2: 17-18.
10. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, et al. Safety and efficacy of Neurobloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53: 1439-1446.
11. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al. Safety and efficacy of Neurobloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53: 1431-1438.
12. Heckmann M, Plewig G. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol 2005; 141: 1255-1259.
13. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003; 49: 34-38.
14. Dressler D, Saberi FA, Benecke R. Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 2002; 249: 1729-1732.
15. Hecht MJ, Birklein F, Winterholler M. Successful treatment of axillary hyperhidrosis with very low doses of botulinum toxin B: a pilot study. Arch Dermatol Res 2004; 295: 318-319.
16. Minor V. Ein neues verfahren zu der klinischen untersuchung der schweissabsonderung. Deutche Z Fur Nervenheilkunde 1927; 101: 302-306.
17. Schlereth T, Mouka I, Eisenbarth G, Winterholler M, Birklein F. Botulinum toxin A (Botox®) and sweating-dose efficacy and comparison to other BoNT preparations. Auton Neurosci 2005; 117: 120-126.
18. Friday D, Bigalke H, Frevert J. In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. International conference on basic and therapeutic aspects of botulinum and tetanus toxins, Hannover, Germany, June 08-12, 2002. Naunyn Schmiedebergs Arch Pharmacol 2002; 365 Suppl 2 R20.